Background Despite several randomized controlled trials and meta-analyses, the ideal
anticoagulant for patients undergoing primary percutaneous coronary intervention (PCI) …

Background: Substantial improvements have been achieved with percutaneous coronary
intervention (PCI) for the treatment of Acute Coronary Syndromes (ACS). Nevertheless …

The immature platelet count (IPC) is a potential marker of platelet reactivity. We assessed
the relationship between IPC during chronic dual antiplatelet therapy (DAPT) and the …

The best treatment options for left main (LM) or multivessel coronary disease (MVD) are still
debated. We performed a meta-analysis of randomized trials comparing percutaneous …

Introduction and objectives Contrasting data have been reported on bivalirudin as an
anticoagulation strategy during percutaneous coronary interventions, offering theoretical …

Background Recent trials have failed to demonstrate any clinical benefit from pre-treatment
with dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary …

Aim: Periprocedural myocardial infarction (PMI), a severe complication of Percutaneous
Coronary Intervention (PCI) procedures, has a negative prognostic effect, both at short and …

Background: The optimization of the strategies for myocardial revascularization has
improved the outcomes of patients with ST-segment elevation myocardial infarction. In …

Introducción y objetivos Se han presentado datos contradictorios respecto al uso de
bivalirudina como estrategia de anticoagulación durante las intervenciones coronarias …

Acute coronary syndromes include a wide spectrum of clinical coronary disease states, from
unstable angina with no observable electrocardiogram changes to ST-segment elevation …